These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 18703609)
1. Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines. Eiblmaier M; Meyer LA; Watson MA; Fracasso PM; Pike LJ; Anderson CJ J Nucl Med; 2008 Sep; 49(9):1472-9. PubMed ID: 18703609 [TBL] [Abstract][Full Text] [Related]
2. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Ping Li W; Meyer LA; Capretto DA; Sherman CD; Anderson CJ Cancer Biother Radiopharm; 2008 Apr; 23(2):158-71. PubMed ID: 18454685 [TBL] [Abstract][Full Text] [Related]
3. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. Niu G; Li Z; Xie J; Le QT; Chen X J Nucl Med; 2009 Jul; 50(7):1116-23. PubMed ID: 19525473 [TBL] [Abstract][Full Text] [Related]
4. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Cai W; Chen K; He L; Cao Q; Koong A; Chen X Eur J Nucl Med Mol Imaging; 2007 Jun; 34(6):850-8. PubMed ID: 17262214 [TBL] [Abstract][Full Text] [Related]
5. Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography. Achmad A; Hanaoka H; Yoshioka H; Yamamoto S; Tominaga H; Araki T; Ohshima Y; Oriuchi N; Endo K Cancer Sci; 2012 Mar; 103(3):600-5. PubMed ID: 22126621 [TBL] [Abstract][Full Text] [Related]
6. Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. Velikyan I; Sundberg AL; Lindhe O; Höglund AU; Eriksson O; Werner E; Carlsson J; Bergström M; Långström B; Tolmachev V J Nucl Med; 2005 Nov; 46(11):1881-8. PubMed ID: 16269603 [TBL] [Abstract][Full Text] [Related]
7. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy. Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420 [TBL] [Abstract][Full Text] [Related]
8. Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice. Cai W; Ebrahimnejad A; Chen K; Cao Q; Li ZB; Tice DA; Chen X Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):2024-36. PubMed ID: 17673999 [TBL] [Abstract][Full Text] [Related]
9. 111In-LLP2A-DOTA Polyethylene Glycol-Targeting {alpha}4{beta}1 Integrin: Comparative Pharmacokinetics for Imaging and Therapy of Lymphoid Malignancies. Denardo SJ; Liu R; Albrecht H; Natarajan A; Sutcliffe JL; Anderson C; Peng L; Ferdani R; Cherry SR; Lam KS J Nucl Med; 2009 Apr; 50(4):625-34. PubMed ID: 19289419 [TBL] [Abstract][Full Text] [Related]
10. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Niu G; Sun X; Cao Q; Courter D; Koong A; Le QT; Gambhir SS; Chen X Clin Cancer Res; 2010 Apr; 16(7):2095-105. PubMed ID: 20215534 [TBL] [Abstract][Full Text] [Related]
12. PET imaging of EGFR expression in nude mice bearing MDA-MB-468, a human breast adenocarcinoma. Sadri K; Ren Q; Zhang K; Paudyal B; Devadhas D; Rodeck U; Thakur M Nucl Med Commun; 2011 Jul; 32(7):563-9. PubMed ID: 21572364 [TBL] [Abstract][Full Text] [Related]
13. Pyo A; Yun M; Kim HS; Kim TY; Lee JJ; Kim JY; Lee S; Kwon SY; Bom HS; Kim HS; Kim DY; Min JJ J Nucl Med; 2018 Feb; 59(2):340-346. PubMed ID: 28916621 [TBL] [Abstract][Full Text] [Related]
14. An EGFR targeted PET imaging probe for the detection of colonic adenocarcinomas in the setting of colitis. Turker NS; Heidari P; Kucherlapati R; Kucherlapati M; Mahmood U Theranostics; 2014; 4(9):893-903. PubMed ID: 25057314 [TBL] [Abstract][Full Text] [Related]
15. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab. Nayak TK; Regino CA; Wong KJ; Milenic DE; Garmestani K; Baidoo KE; Szajek LP; Brechbiel MW Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1368-76. PubMed ID: 20155263 [TBL] [Abstract][Full Text] [Related]
16. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066 [TBL] [Abstract][Full Text] [Related]
17. Comparison of conjugation strategies of cross-bridged macrocyclic chelators with cetuximab for copper-64 radiolabeling and PET imaging of EGFR in colorectal tumor-bearing mice. Zeng D; Guo Y; White AG; Cai Z; Modi J; Ferdani R; Anderson CJ Mol Pharm; 2014 Nov; 11(11):3980-7. PubMed ID: 24720806 [TBL] [Abstract][Full Text] [Related]
18. Non-invasive PET imaging of EGFR degradation induced by a heat shock protein 90 inhibitor. Niu G; Cai W; Chen K; Chen X Mol Imaging Biol; 2008; 10(2):99-106. PubMed ID: 18157579 [TBL] [Abstract][Full Text] [Related]
19. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model. Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064 [TBL] [Abstract][Full Text] [Related]